Salvador Augustín

β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial

Càndid Villanueva, Agustı́n Albillos, Joan Genescà et al. · The Lancet · 2019 · 671 citations

Medicine, Pharmacology, Pharmacotherapy +8

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue et al. · Journal of Hepatology · 2020 · 466 citations

Medicine, Internal Medicine, Pharmacotherapy +12

A Histologic Scoring System for Prognosis of Patients With Alcoholic Hepatitis

José Altamirano, Rosa Miquel, Aezam Katoonizadeh et al. · Gastroenterology · 2014 · 418 citations · Full text

Medicine, Internal Medicine, Pathology +13

A MELD-Based Model to Determine Risk of Mortality Among Patients With Acute Variceal Bleeding

Enric Reverter, Puneeta Tandon, Salvador Augustín et al. · Gastroenterology · 2013 · 398 citations · Full text

Business, Biostatistics, Internal Medicine +16

Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: The “Anticipate” study

Juan G. Abraldeṣ, Christophe Bureau, Horia Ştefănescu et al. · Hepatology · 2016 · 376 citations

Medicine, Internal Medicine, Clinical Epidemiology +16